PIK3CA and neoplasm: One significant development in the PI3K arena is the emerging, compelling evidence that targeting of p110β with selective small molecule inhibitors may provide therapeutic benefit in the treatment of autoimmune diseases [19], as well as in the treatment of specific (PTEN-null) tumour types [12].